NeuroSense Therapeutics Q1 2024 Earnings Report

NeuroSense Therapeutics EPS Results

• Actual EPS: -$0.35
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

NeuroSense Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

NeuroSense Therapeutics Announcement Details

• Quarter: Q1 2024
• Date: 6/24/2024
• Time: N/A
• Conference Call Date: Monday, June 24, 2024
• Conference Call Time: 7:00AM ET

NeuroSense Therapeutics (NASDAQ:NRSN), Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration. By combining high-throughput screening with advanced medicinal chemistry and in vivo disease models, the company is advancing multiple small-molecule preclinical candidates toward Investigational New Drug (IND)-enabling studies. Key areas of focus include Alzheimer’s disease, Parkinson’s disease and other brain disorders linked to aging and cellular dysfunction.

Founded by a team of neuroscientists and drug-discovery experts, NeuroSense is headquartered in Tel Aviv, Israel, with research operations extending to the United States. The company has established collaborations with leading academic institutions and contract research organizations to support its pipeline development. NeuroSense’s executive leadership brings extensive experience in biotechnology and pharmaceutical development, positioning the firm to translate its innovative science into potential new treatments for patients worldwide.